文献速递心脑血管急症复苏、休克与脓毒症

院前抗血小板治疗用于疑似急性冠脉综合征的院外心脏骤停患者

Prehospital antiplatelet therapy in patients with out-of-hospital cardiac arrest suspected of acute coronary syndrome.
PubMed 文献 · Resuscitation · 2025-03-28
一句话结论院前抗血小板治疗在疑似ACS的OHCA患者中安全,但未显示改善30天生存或心血管结局。

本研究纳入2012至2024年院外心脏骤停(OHCA)后24小时内转至心导管室行冠状动脉造影的连续患者411例,217例(52.8%)接受院前抗血小板治疗(阿司匹林单药44.5%或阿司匹林联合P2Y12抑制剂8.3%)。采用逆概率加权比较发现,接受与未接受院前抗血小板治疗的患者30天全因死亡无差异(56.7%[50.0%;63.1%] vs 59.8%[52.8%;66.4%],p=0.280),院内MACE和主要出血率亦无显著差异,结果在ST段抬高或成功复苏亚组中似乎一致。结论认为院前抗血小板治疗安全,但未显示明显改善生存或心血管结局。

要点

  • 411例OHCA疑似ACS患者中,52.8%接受院前抗血小板治疗(阿司匹林单药44.5%,阿司匹林联合P2Y12抑制剂8.3%)。
  • 院前抗血小板治疗组与未治疗组30天全因死亡无差异:56.7%[50.0%;63.1%] vs 59.8%[52.8%;66.4%],p=0.280。
  • 院内MACE和主要出血(BARC ≥ 3)率在两组间无显著差异。
  • 结果在ST段抬高或成功复苏的亚组患者中似乎一致。
  • 结论:院前抗血小板治疗安全,但未显示明显改善生存或心血管结局。

适用人群与场景

  • OHCA后24小时内转至心导管室行冠状动脉造影的连续患者,2012年至2024年纳入。
  • 疑似急性冠脉综合征(ACS)的OHCA患者。

研究设计与关键结果

  • 研究类型:基于连续患者的观察性研究,采用逆概率加权比较两组结局。
  • 样本量:411例,其中217例(52.8%)接受院前抗血小板治疗。
  • 干预:院前抗血小板治疗定义为入心导管室前给予阿司匹林单药和/或P2Y12抑制剂;阿司匹林单药占44.5%,阿司匹林联合P2Y12抑制剂占8.3%。
  • 主要终点:30天全因死亡,接受院前治疗组56.7%[50.0%;63.1%] vs 未接受组59.8%[52.8%;66.4%],p=0.280。
  • 次要终点:院内MACE(全因死亡、心肌梗死、支架血栓或卒中的复合终点)和院内主要出血(BARC ≥ 3)率在两组间无显著差异。
  • 亚组:结果在ST段抬高或成功复苏的患者中似乎一致。

证据类型、等级与局限

  • 证据类型:观察性研究,采用逆概率加权分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于OHCA疑似ACS患者,院前抗血小板治疗安全,但未显示明显改善生存或心血管结局。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: There are currently no specific guidelines for prehospital antiplatelet therapy in patients with out-of-hospital cardiac arrest (OHCA) associated with acute coronary syndrome (ACS). This study aims to evaluate the efficacy and safety of a prehospital antiplatelet loading dose in patients with OHCA suspected of ACS referred to a cardiac catheterization laboratory (cath lab).

METHODS: We included consecutive patients referred for coronary angiography within 24 h after OHCA from 2012 to 2024. Prehospital antiplatelet treatment was defined as prescribing aspirin alone and/or a P2Y12 inhibitor before admission to the cath lab. Outcomes included: all-cause death at 30 days, in-hospital major adverse cardiovascular events (MACE), defined as a composite of all-cause death, myocardial infarction, stent thrombosis, or stroke, and in-hospital major bleeding (BARC ≥ 3). An inverse probability weighting approach was used to compare outcomes between the two groups.

RESULTS: Of the 411 patients admitted to the cath lab within 24 h after OHCA, 217 (52.8%) received prehospital antiplatelet therapy, either aspirin alone (44.5%) or aspirin plus a P2Y12 inhibitor (8.3%). There was no difference in 30-day all-cause death between patients who received a prehospital treatment and those who did not (56.7%[50.0%;63.1%] vs 59.8%[52.8%;66.4%], p = 0.280). Rates of in-hospital MACE and major bleeding were not significantly different between the two strategies. Results appear to be consistent in subgroups of patients with ST-segment elevation or successfully resuscitated patients.

CONCLUSIONS: Prehospital antiplatelet therapy was safe, but showed no apparent improvement in survival or cardiovascular outcomes in patients with OHCA suspected of ACS.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Charleux P, Chommeloux J, Elhadad A, et al. Prehospital antiplatelet therapy in patients with out-of-hospital cardiac arrest suspected of acute coronary syndrome. Resuscitation. 2025. PMID: 40158681. doi:10.1016/j.resuscitation.2025.110596

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。